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Abstract
Introduction. Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease which becomes 
a rapidly growing health problem in the Western countries. The development of the disease is most often connected 
to obesity. NAFLD is also considered as the hepatic manifestation of metabolic syndrome. Transforming growth 
factor b1 (TGF-b1) plays an important role in the pathogenesis of liver fibrosis, being involved in activation of 
hepatic stellate cells, stimulation of collagen gene transcription, and suppression of matrix metalloproteinase 
expression. The objective of the study was to evaluate by immunohistochemistry the expression of TGF-b1 in 
the liver tissue of NAFLD patients and correlate it with anthropometric, biochemical and routine histological 
parameters.
Material and methods. The study group consisted of 48 patients with diagnosed NAFLD. Liver steatosis, NAFLD 
Activity Score (NAS) and METAVIR score of fibrosis were evaluated in liver biopsies. The immunoreactivity 
of TGF-b1 was evaluated semi-quantitatively separately in portal, septal, lobular hepatocytic and lobular sinu-
soidal liver compartments. The results were analyzed in regard to patients’ clinical and biochemical parameters. 
Results. Neither steatosis nor NAS correlated with TGF-b1 expression in any liver compartment, whereas 
METAVIR score of fibrosis was associated with increased immunoreactivity of TGF-b1 in most of the studied 
liver compartments. TGF-b1 immunoreactivity showed positive correlation with patients’ age and its expression 
in septal compartment disclosed positive correlation with body mass index, and waist and hip circumference. 
Hyaluronic acid serum level was positively and iron concentration was negatively associated with TGF-b1 ex-
pression in the selected consecutive liver compartments.
Conclusions. The immunohistochemical expression of TGF-b1 may be complementary to routine methods of 
liver fibrosis evaluation. (Folia Histochemica et Cytobiologica 2019, Vol. 57, No. 2, 74–83)
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is 
a common chronic liver disease which becomes 
a rapidly growing health problem in developed coun-
tries affecting approximately 30% of population [1]. 
Its worldwide prevalence continues to increase with 
the growing problem of obesity [2]. NAFLD involves 
several liver conditions: simple steatosis, non-alco-
holic liver steatohepatitis (NASH), hepatic cirrhosis 
and hepatocellular carcinoma (HCC). NAFLD is 
strongly associated with the metabolic syndrome [3]. 
The course of NAFLD differs between patients and 
most of them do not develop more advanced forms of 
the disease. However, 20% of patients with NAFLD 
progress to NASH and 30% of patients with NASH 
have liver fibrosis [1]. Age above 50 years and preex-
isting fibrosis are well established factors that increase 
the risk of cirrhosis in the course of NAFLD [4]. 
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Additionally, NAFLD-associated non-cirrhotic HCC 
is a currently recognized problem [5].
Transforming growth factor (TGF) b1 is one of the 
most important cytokines accelerating liver fibrosis 
[6]. TGF-b1 promotes activation of hepatic stellate 
cells (HSCs), stimulates collagen gene transcription, 
and suppresses expression of matrix metallopro-
teinases. Therefore, TGF-b1 signaling represents 
a potential therapeutic target in liver fibrosis treatment. 
Additionally, TGF-b1 signaling pathway can interfere 
with hepatocyte proliferation and accelerate HCC 
progression. TGF-b1 has been reported to play both 
tumor-suppressive and tumor-promoting roles [7–9]. 
Although liver biopsy is still a gold standard to 
estimate fibrosis stage, new techniques are now under 
validation for noninvasive fibrosis evaluation, e.g. 
serum marker panels [10], elastography [11], and 
functional breath tests [12]. 
The objective of this study was to evaluate the 
expression of TGF-b1 in the liver tissue of patients 
with NAFLD and to correlate it with anthropometric, 
biochemical and classical histological parameters. 
Material and methods
Patients. The study group consisted of 48 consecutive 
patients with NAFLD diagnosed in Department of Gastro-
enterology and Hepatology, Wroclaw Medical University 
between 2015 and 2017. The diagnosis was made based on 
the American Association for the Study of Liver Diseases 
(AASLD) guidelines [13]. None of 48 consecutive patients 
with NAFLD had normal body weight index (BMI 18.5–25). 
Eighteen (40.9%) patients were overweight (BMI 25–30) 
and 26 (59.1%) were obese (BMI > 30). Mean age of the 
patients was 46.1 years; no significant difference in the mean 
age was found between sexes. Characteristics of the patients 
are shown in Table 1. NAFLD was confirmed by histological 
examination of liver biopsies (> 5% of hepatocytes con-
taining fat droplets). Indications for liver biopsy included 
suspicion of steatohepatitis or liver fibrosis in the course 
of steatosis. Other causes of steatosis were excluded: viral 
hepatitis, autoimmune hepatitis, hemochromatosis, Wilson’s 
disease, a-1 antitrypsin deficiency and drug-induced hepatic 
injury. Consumption of ethanol higher than 30 mg/day for 
men and 20 mg/day for women was also the exclusion cri-
terion. Complete clinical examination with anthropometric 
measurements and laboratory sampling was performed in all 
subjects at the beginning of the study. The anthropometric 
data included body mass, height, body mass index (BMI) 
calculated as weight (kg) divided by height squared (m2), 
waist circumference (WC), hip circumference (HC), waist-
-to-hip ratio and waist-to-height ratio.
Laboratory tests. Standard blood morphology, liver bio-
chemical tests, serum lipids, fasting glucose, insulin, C-reac-
tive protein, glycated hemoglobin (HbA1c), C-peptide, iron 
and ferritin concentrations were measured. Additionally, 
serum was collected for potential markers of inflamma-
tion/fibrosis in the liver: hyaluronic acid, fibronectin, 
alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, 
TGF-b1 and TNF. Homeostasis model assessment of insulin 
resistance (HOMA-IR) was calculated using the following 
formula: HOMA-IR = fasting glucose (mg/dL) × fasting 
insulin (μU/mL)/405 [14]. History of concomitant diseas-
es/medication was obtained. The diagnosis of metabolic 
syndrome was established according to Adult Treatment 
Panel III criteria [15]. The study protocol was approved 
by local ethics committee with compliance to the Helsinki 
Declaration. Informed written consent was obtained from 
each patient before enrollment to the study.
Histopathology. Histological examinations of all samples 
were performed by the same pathologist. All specimens were 
considered representative (sample length > 1.5 cm). After 
the percentage involvement by steatotic hepatocytes was 
assessed, the patients were divided into subgroups: 5–33% 
mild, 33–66% moderate or > 66% severe steatosis. NASH 
Clinical Research Network system for scoring activity and 
fibrosis in NAFLD was used to calculate NAFLD Activity 
Score (NAS) ranging 0–8 [16]. Patients with NAS score 0–2 
were considered as not having NASH, patients with score 
5–8 were diagnosed NASH. Activity scores 3 and 4 were 
noted as borderline cases (borderline NASH). The staging 
of fibrosis was assessed using METAVIR score [17] (F0: no 
fibrosis, F1: portal fibrosis without septa, F2: portal fibrosis 
with few septa, F3: numerous septa without cirrhosis, F4: 
cirrhosis). 
Immunohistochemistry. From 10% formalin-fixed par-
affin embedded blocks 5 μm-thick sections were cut with 
microtome and mounted on sialinized slides (code number 
S3003; DAKO, Glostrup, Denmark). Next, they underwent 
automated dewaxing, rehydration and heat-induced epitope 
retrieval in PT Link Pre-Treatment Module for Tissue Spec-
imens (DAKO), with EnVision Target Retrieval Solution 
(DAKO) used for 30 min incubation at 97°C. Immunohis-
tochemical (IHC) reaction with TGF-b1 rabbit polyclonal 
antibody (No. PA5-32628, 1:100 Thermo Scientific Pierce 
Products, Waltham, MA, USA) was performed in Auto-
stainer Link 48 (DAKO) and EnVision FLEX/HRP system 
(DAKO) was used for detection. Positive and negative con-
trol slides were prepared. As a negative control, liver core 
biopsy was processed in the abovementioned sequences, but 
FLEX Mouse Negative Control, Ready-to-Use (DAKO) 
was used instead of the primary antibody. Human brain 
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tissue was used for positive controls. Evaluation of TGF-b1 
expression was performed with Olympus BX41 microscope 
by the same pathologist. TGF-b1 expression was evaluated 
in following compartments: portal (PC), septal (SC), lobular 
hepatocytic (LCH) and lobular sinusoidal (LCS). Compart-
ments for the evaluation of IHC reactivity were distinguished 
by the authors based on the anatomical structure of the liver 
in attempt to diversify the significance of TGF-b1 in various 
histological regions of this organ. 
Evaluation of the intensity of TGF-b1 immunoreactivity. 
The assessment of TGF-b1 expression in each compartment 
was based on the intensity of the IHC reaction; specimens 
were given points according to the following scale: no re-
activity — 0, weak reactivity — 1, moderate reactivity — 2, 
strong reactivity — 3. In LCH and LCS compartments, 
TGF-b1 expression was also evaluated according to a mod-
ified scale of Remmele [18], in which two parameters were 
considered: percentage of cells with positive cytoplasmatic 
immunoreactivity (percentage of reactive area) and intensity 
of staining (Table 2). Final score (0–12 pts.), named Immu-
noreactive Score (IRS), was calculated by multiplication of 
points given for percentage of positive cells (0–4 pts.) and 
intensity of reaction (0–3 pts.).
Statistical analysis. Continuous, normally distributed varia-
bles were expressed as mean ± standard deviation. Student’s 
t-test was performed to compare the means between groups 
Table 1. Selected clinical characteristics of patients with non-alcoholic fatty liver disease (n = 48)
Age (years)  46.1 ± 10.9 (M: 45.9 ± 9.9; F: 46.3 ± 11.1)
Sex (female/male) 17/31 (35.4%; 54.6%)
Weight [kg] 093.0 ± 16.7 (M: 95.6 ± 14.4; F: 90.1 ± 12.4)
BMI [kg/m2] 30.9 ± 4.0 (M: 30.1 ± 3.6; F: 32.9 ± 4.2)
HC [cm] 107.1 ± 8.6 (M: 105 ± 7.2; F: 112.3 ± 9.5)
WC [cm] 107.6 ± 9.3 (M: 107.0 ± 9; F: 109 ± 9.7)0000
WHR 1.004 ± 0.09 (M: 1.02 ± 0.04; F: 0.97 ± 0.04)
WHtR 000.61 ± 0.06 (M: 0.6 ± 0.06; F: 0.61 ± 0.05)
Serum values
Glucose (< 100 mg/dL) 112.9 ± 47.1
Insulin (μU/mL) 013.1 ± 10.2
HbA1c (3–6.5%) 5.87 ± 0.9
C-peptide [ng/ml] 3.79 ± 2.4
ALT (< 35 U/I) 073.3 ± 33.6
AST (< 31 U/I) 053.0 ± 26.5
GGT (< 38 U/I) 082.8 ± 47.6
Alkaline phosphatase (30–120 U/I) 096.4 ± 37.1
TG (< 150 mg/dl) 0233.2 ± 140.1
Iron (70–180 μg/dl) 103.42 ± 38.10
Hyaluronic acid [ng/ml] 29.47 ± 14.1
Haptoglobin [g/l] 1.66 ± 0.9
TGF-b1 [ng/ml] 6.42 ± 3.1
HOMA-IR 02.54 ± 2.54
Clinical status
Hypertension 27 (56.2%)
Diabetes 14 (29.2%)
Dyslipidemia 20 (41.7%)
Metabolic syndrome 19 (39.6%)
Values represent mean ± SD or the number of patients with percentages in parentheses. Abbreviations: BMI — body mass index; HC — hip circum-
ference; WC — waist circumference ;WHR — waist to hip ratio; WHtR — waist  to height ratio; ALT — alanine transaminase; AST — aspartate 
transaminase; GGT — gamma-glutamyl-transferase; TG — triglycerides; HOMA-IR — homeostasis model assessment of insulin resistance.
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with normally distributed data. In non-parametric samples, 
Mann-Whitney U-test was used. Normality of distribution 
was evaluated with Shapiro-Wilk test. Associations between 
normally distributed data were analyzed using Pearson 
correlation coefficient and Spearman correlation was per-
formed in non-parametric data series.
Results
The immunoreactivity of TGF-b1 in the classified 
liver compartments
Cytoplasmic TGF-b1 expression was observed in 
various cells of all analyzed liver compartments: 
besides expression in lobular hepatocytes, TGF-b1 
reactivity was present in parasinusoidal stellate cells, 
sinusoidal Kupffer cells, other infiltrating immune 
cells as well as fibroblasts in PC and SC (Fig. 1). The 
distribution of TGF-b1 immunoreactivity in respec-
tive compartments, assessed as the intensity of the 
IHC reaction, is shown in Figure 2. The intensity of 
TGF-b1 immunoreactivity was compared in pairs 
between consecutive compartments. The intensity of 
TGF-b1 immunoreactivity was significantly lower in 
septal compartment compared with every other com-
partment (Mann-Whitney U-test, p < 0.001, Fig. 3). 
Additionally, the TGF-b1 immunoexpression in lob-
ular hepatocytic compartment was significantly lower 
compared to either portal compartment or lobular 
Table 2. Modified scale of Remmele used for evaluation of immunohistochemistry [18] 
Percentage of cells with positive cytoplasmatic reaction Points Intensity of color reaction Points
No cells with reaction 0 No reaction 0
< 25% cells with positive reaction 1 Weak reaction 1
25–50% cells with positive reaction 2 Moderate reaction 2
51–75% cells with positive reaction 3 Intensive reaction 3
> 75% with positive reaction 4  
Figure 1. The immunoreactivity of TGF-b1 in liver sections. A. Massive hepatic steatosis; low TGF-b1 expression in lobular 
hepatocytic and lobular sinusoidal compartments. B. Centrilobular zone with mild steatosis; moderate TGF-b1 immunore-
activity in lobular hepatocytic and lobular sinusoidal compartments, mostly adjacent to the central vein. C. Minimal hepatic 
steatosis, periportal and lobular zone; high TGF-b1 expression in lobular hepatocytic compartment. D. Moderate hepatic 
steatosis, portal triad zone; high TGF-b1 expression in portal and lobular hepatocytic compartments. TGF-b1 immunoreac-
tivity was visualized in the sections of human liver biopsies as described in Methods. 
A B
C D
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sinusoidal compartment (Mann-Whitney U-test, 
p < 0.05, Fig. 3). The distribution of TGF-b1 immu-
noreactivity in LCH and LCS, expressed by the IRS 
score, is shown in Figure 4. 
In intercompartmental analysis of TGF-b1 expres-
sion we observed positive correlations between inten-
sity of staining in respective compartments (Table 3). 
TGF-b1 immunoreactivity and clinical  
characteristics of the NAFLD patients
Associations between TGF-b1 expression and selected 
clinical parameters are shown in Table 4. Interest-
ingly, TGF-b1 immunoexpression correlated with 
Intensity of TGF-b1 reaction in different compartments (0–3)
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Figure 2. Distribution of the intensity of TGF-b1 immunoreactivity in respective compartments of the human liver in patients 
with non-alcoholic fatty liver disease.
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Figure 3. Mean intensity of TGF-b expression in respective compartments of the human liver in patients with non-alcoholic 
fatty liver disease. Abbreviations: LCH — lobular hepatocytic; LCS — lobular sinusoidal; PC — portal; SC — septal). Data 
are presented as mean SD. *p < 0.001 Septal compartment (SC) compared to PC, LCH, LCS compartments. **p < 0.05 
LCH compared to PC and LCS compartments.
patients’ age in most compartments. No significant 
differences between sexes were found concerning 
age. Natural differences in some anthropometric 
parameters were found between sexes (e.g. higher 
waist-to-hip ratio, i.e. WHR, in men). Moderate pos-
itive correlations were found between the intensity of 
reaction in septal compartment and BMI, waist and 
hip circumference (p < 0.05). 
TGF-b1 immunoexpression and laboratory  
findings in NAFLD patients
The analysis of TGF-b1 expression versus laboratory 
parameters revealed moderate negative correlation 
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with serum iron levels. Negative correlations between 
iron levels and TGF-b1 immunoreactivity were ob-
served in SC, LCH and LCS, whereas moderate posi-
tive correlations with haptoglobin, hyaluronic acid and 
serum TGF-b1 (Table 4). No correlations were found 
between TGF-b1 expression in any compartment and 
following parameters: components of blood morphol-
ogy, alanine transaminase, aspartate transaminase, 
gamma-glutamyl-transferase, alkaline phosphatase, 
serum lipids, ferritin concentration and HOMA (data 
not shown). Also, no correlations between the expres-
sion of TGF-b1 in any compartment and fibronectin, 
alpha-2-macroglobulin, apolipoprotein A1 and TNF 
were found (data not shown). 
TGF-b1 expression and histopathological  
characteristics
Neither liver steatosis nor activity of NAFLD (NAS 
score) were associated with TGF-b1 immunoreactiv-
ity. However, both the intensity and IRS of TGF-b1 
expression in LCH were weakly, positively associated 
with the stage of liver fibrosis. Similar weak associa-
tion was observed in PC, whereas moderate correla-
tion with fibrosis was found in SC (Table 4). 
Discussion
Liver fibrosis results from the excessive accumulation 
of extracellular matrix proteins including collagen that 
occurs in most types of chronic liver diseases [19]. Fi-
brosis may affect also other organs such as kidneys and 
heart, leading to significant changes in their structure 
and function [20, 21]. There is a wide range of factors 
causing fibrosis, such as infections, ischemia, radiation 
or injuries [22–24] and proinflammatory cytokines 
are thought to be involved in its initiation [25]. It 
was found that key roles in regulating promotion and 
acceleration of fibrosis are played by members of the 
TGF-b superfamily [26]. The members of the TGF-b 
family belong to the group of the most pleiotropic 
cytokines, involved in many physiological pathologic 
processes, e.g. inflammation, tissue repair, cell migra-
tion as well as cell differentiation and apoptosis [27]. 
Studies on TGF-b functions led to development of 
targeted therapies in kidney and lung fibrosis [28, 29] 
and in cancer [30]. Accordingly, fibrosis in the course 
of NAFLD emerges as one of the possible therapeutic 
targets, next to hepatic steatosis and metabolic stress, 
bile acid-farnesoid X receptor axis, de novo lipogene-
sis, incretins- and fibroblast growth factors-dependent 
pathways, inflammation and injury [31].
Furthermore, it has been recently demonstrated that 
fibrosis stage affects liver-related mortality in patients with 
NAFLD [32]. Moreover, it predicted overall- and dis-
ease-specific survival among patients with NAFLD [33].
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Figure 4. Immunoreactivity score (IRS) in lobular compartments of the human liver in patients with non-alcoholic fatty 
liver disease.
Table 3. Correlations between intensity of TGF-b1 immuno-
reactivity in the analyzed liver compartments of liver biopsies 
in patients with non-alcoholic fatty liver disease
PC SC LCH LCS
PC 1.0
SC 0.61* 1.0
LCH 0.45* 0.62* 1.0
LCS 0.44* 0.46* 0.42* 1.0
Values express Spearman correlation coefficients. Abbreviations: PC 
— portal compartment; SC — septal compartment; LCH — lobular 
hepatocytic compartment; LCS — lobular sinusoidal compartment. 
SIMILARLY AS IN TABLE 4; *p < 0.01.
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In recognition of the functional and structural 
heterogeneity of liver histology, we decided to eval-
uate TGF-b1 expression in various compartments: 
periportal, septal and lobular. This division enabled 
characterization of the spatial distribution of TGF-b1 
in the liver tissue and more detailed analysis of pos-
sible correlations between TGF-b1 reactivity and 
other clinicopathological parameters. In sinusoidal 
and hepatocytic compartments, TGF-b1 staining 
was evaluated by two methods: intensity of immu-
noreactivity reaction and ImmunoReactive Score, as 
described in Methods). The latter technique addi-
tionally takes into account the percentage area of the 
reactive tissue. Overall, both methods led to similar 
results when TGF-b1 expression was correlated with 
other clinicopathological parameters. The immuno-
expression of TGF-b1 was found in various cells of 
all hepatic compartments: hepatocytes, stellate cells, 
Kupffer cells, infiltrating immune cells and fibroblasts. 
Intercompartmental correlations were strongly pos-
itive. IHC reactivity of TGF-b1 was the strongest in 
LCS, which highlights the role of Kupffer cells and 
parasinusoidal hepatic stellate cells as a source of 
fibrosis-driving TGF-b1. The intensity of the IHC 
reaction was the least pronounced in SC, where the 
fibrosis evaluated in METAVIR scoring system is 
usually described. In this compartment TGF-b1 ex-
pression showed strongest positive correlation with 
the stage of fibrosis (METAVIR). TGF-b1 expression 
did not depend on the stage of liver steatosis. Also, 
the intensity of inflammation evaluated as NAS did 
not correlate with TGF-b1 reactivity. 
To the best of our knowledge, the distribution 
of TGF-b1 has not been comprehensively studied 
in patients with NAFLD. However, Farrington et 
al. studied TGF-b1 expression in fibrotic livers in 
patients with biliary atresia [34]. They analyzed two 
areas, portal and lobular, and found that TGF-b1 was 
present predominantly in the latter. Consistently, we 
observed highest TGF-b1 reactivity in lobular com-
partments. However, periportal staining for TGF-b1 
was also prominent in our study. This discrepancy may 
be related to the depletion of bile ducts in advanced 
biliary atresia. Biliary epithelium is known to be 
a source of TGF-b1 and thus contributes to fibrosis [35].
In standard histological liver scoring systems most 
attention is paid to the periportal and septal regions. 
Our study showed that TGF-b1distribution is diffused 
Table 4. Correlations between the intensity of TGF-b1 immunoreactivity in respective liver compartments, age and selected 
anthropometric, laboratory and histopathological parameters
PC SC LCH LCS LCH-IRS LCS-IRS
Age 0.29* 0.42** 0.17 0.22 0.31* 0.34*
Anthropometric parameters
Weight 0.01 0.18 0.05 0.20 0.00 0.15
BMI 0.20 0.49** 0.10 0.24 0.14 0.25
HC 0.22 0.53** 0.25 0.16 0.23 0.21
WC 0.18 0.43** 0.07 0.23 0.13 0.24
WHR –0.05 –0.12 –0.26 0.05 –0.13 0.07
Serum parameters
HbA1c 0.19 0.31* 0.19 –0.03 0.26 0.05
C-peptide 0.20 0.31* 0.14 0.08 0.08 0.01
Iron –0.11 –0.37** –0.38** –0.32** –0.32** –0.31**
Hyaluronic acid 0.36* 0.37** 0.26 0.21 0.35* 0.16
Haptoglobin 0.01 0.37** 0.25 0.03 0.17 0.12
TGF-b1-serum 0.21 0.38** 0.26 0.15 0.13 0.22
Histopathological indices
Steatosis 0.19 0.25 0.09 0.14 0.18 0.17
NAS score –0.18 –0.02 –0.09 –0.19 –0.13 –0.26
Fibrosis 0.32* 0.41** 0.28* 0.18 0.29* 0.16
Values represent correlation coefficients. The intensity of the TGF-b1 immunoreactivity was assessed as described in Methods. Abbreviations: same 
as in the legend to Table 1 and Table 3; LCH-IRS, lobular hepatocytic compartment assessed by ImmunoReactive Score; LCS-IRS lobular sinusoidal 
compartment assessed by ImmunoReactive Score. *p < 0.05; **p < 0.01.
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in liver lobules and not only limited to periportal and 
septal regions.
Considering anthropometrical data, we found 
that intensity of TGF-b1 expression in SC correlated 
with BMI, waist and hip circumference, but not with 
absolute weight and waist-to-hip ratio. This indirectly 
suggests that BMI better than WHR predicts liver 
fibrosis. Our observation is in line with the reports 
of other authors. Angulo et al. implemented BMI in 
NAFLD Fibrosis Score, which is a well-established 
non-invasive system identifying liver fibrosis in 
NAFLD patients [36].
In our study we correlated selected biochemical 
parameters with the intensity of TGF-b1 expression 
in the liver. We found positive associations with serum 
concentrations of HbA1c, C-peptide and hyaluronic 
acid, haptoglobin, and TGF-b1 in septal compart-
ment. This is not surprising since haptoglobin in well-
known marker of liver fibrosis and is incorporated 
in Fibrotest formula [37]. Serum concentration of 
hyaluronic acid seems to be biomarker of fibrosis in 
chronic liver diseases of different etiologies [38] such 
as non-alcoholic fatty liver disease [39], alcoholic fatty 
liver disease [40], and viral hepatitis [41]. 
An interesting, unexpected observation was the 
finding of a reverse correlation between TGF-b1 im-
munoreactivity in most liver compartments and serum 
iron concentration. Trying to explain this phenome-
non in humans we conjecture on a possible negative 
feedback mechanism that limits liver fibrosis. TGF-b1 
was recently recognized as an activator of hepcidin 
mRNA expression in isolated human hepatocytes 
[42]. Hepcidin maintains serum iron concentration 
by controlling dietary uptake of iron from duodenal 
enterocytes. It binds to cellular ferroportin to trigger 
its internalization and degradation, which blocks the 
transport of iron from enterocytes to portal circula-
tion [43]. TGF-b1 downregulates iron serum level in 
a hepcidin-dependent mechanism [44] which might 
explain the inverse correlation between iron levels 
and TGF-b1 expression in our study. However, in 
an animal model Han et al. [45] showed decreased 
activation of hepatic stellate cells and TGF-b1 effect 
by hepcidin. The authors demonstrated an inhibition 
of Smad3 phosphorylation in HSCs by hepcidin which 
may account for the anti-fibrotic effect of hepcidin. 
Based on this experimental study, a new model of 
fibrosis downregulation can be proposed: activation of 
HSCs results in TGF-b1 synthesis and secretion that 
increases hepcidin expression. The overexpression 
of hepcidin, in turn, downregulates HSCs activation 
and thus self-limits liver fibrosis. Thus, studies of new 
fibrosis markers may lead not only to the improvement 
of the scoring systems but also to the development of 
the new therapeutic strategies. It has to be noted that 
one of the limitations of our study is fact that majority 
of patients were men although this is consistent with 
the results of the epidemiological studies [46].
Conclusions
TGF-b1 might be a promising immunohistochemical 
marker of the liver fibrosis in NAFLD patients; how-
ever, further studies on larger group of patients with 
NAFLD are required. 
The assessment of the immunohistochemical re-
activity of TGF-b1 can be complementary to routine 
methods of liver fibrosis evaluation. 
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